Latest information on COVID-19

Blood & Marrow Transplantation

Message From the Chief

Welcome to the Division of Blood and Marrow Transplantation. We are very proud of the outstanding compassionate care that we provide our patients along with conducting state of the art basic and translational science on stem cell biology, cellular immunology and transplantation biology.

About Us

The BMT program at Stanford performs autologous and allogeneic transplantations for over 450 patients each year. The program has been very successful with a history of limited morbidity rates and acute mortality that is well below most published reports.

Make a Gift

Our cutting-edge research is developing novel immunotherapy for cancer. Support the BMT Division by making a donation to our research fund.


Latest News

  • Precision Medicine: New Technology That Changes the Clinical Practice

    In order to monitor disease after a curative treatment such as allogeneic transplant, pioneer works from Drs. David Miklos and Wen-Kai Weng have established the utility of high-throughput sequencing (HTS) of either B-cell receptor (BCR) or T-cell receptor (TCR) in monitoring minimal residual disease (MRD).

  • Teaching a young dog new tricks: Story of a kinase and its inhibitor

    The development of normal lymphocytes is a well-orchestrated process, that begins in the bone marrow. This process involves a functional antigen receptor (B-cell receptor or T-cell receptor) and a dozen of intermediators, including adaptor proteins and kinases that form a network of signaling pathways inside the cells.


Over 400 patients received bone marrow or stem cell transplants at Stanford last year.  


Division Events